Learn More
BACKGROUND Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses associated with psoriasis. OBJECTIVES ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice(More)
BACKGROUND Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. OBJECTIVE Assess long-term safety of oral(More)
OBJECTIVES This study aimed to estimate rates of cancer or opportunistic infection in patients with psoriatic arthritis (PsA) compared with patients without PsA. METHODS Using the Clinical Practice(More)